Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-prolyl isomerase NIMA-interacting 1 (PIN1)
- Target
- PIN1
- Molecular classification
- Enzyme, Peptidyl-prolyl isomerase (PPIase), Post-translational modification enzyme
01
Overview
Peptidyl-prolyl isomerase NIMA-interacting 1 (PIN1) is an 18 kDa enzyme with a unique ability to catalyze the cis-trans isomerization of phosphorylated Ser/Thr-Pro motifs in proteins. This function acts as a molecular switch, profoundly regulating signal transduction, protein stability, subcellular localization, and interactions. PIN1 controls critical cellular processes including cell cycle progression, cell proliferation, DNA damage response, apoptosis, and immune regulation. Dysregulation of PIN1 is implicated in a spectrum of diseases—its overexpression drives oncogenesis and cancer progression, while its deficiency contributes to neurodegeneration and impaired immune function. As the only PPIase specific for phosphorylated motifs, PIN1 represents a strategic therapeutic target, with ongoing research focused on developing domain-specific inhibitors to treat cancer and inflammatory diseases.
- Other names
- Pin1Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Peptidyl-prolyl isomerase PIN1Rotamase PIN1
02
Mechanism of action
Competitive inhibition of the PPIase catalytic domain; Allosteric inhibition targeting the WW domain; Prevention of substrate binding and isomerization, inhibiting downstream signaling essential for tumor progression
03
Biological functions
Cell cycle regulation (especially G2/M transition)Protein folding and maturationRegulation of signal transduction (MAPK, CDK, GSK3 pathways)Cell proliferationImmune response modulationRegulation of apoptosisDNA damage response and repairCell survival
04
Disease associations
Cancer (upregulated in many cancers and promotes oncogenic pathways)Neurodegenerative disease (downregulation implicated in Alzheimer's disease)Cardiovascular disease (regulates vascular homeostasis and cardiac hypertrophy)Inflammation (through modulation of immune and endothelial pathways)Autoimmune disease (regulatory network hub in autoimmunity)
05
Safety considerations
Potential impact on normal proliferative tissues due to broad PIN1 functionOff-target effects given PIN1's ubiquity and broad regulatory scopeImmunosuppression and neurotoxicity risks due to roles in immune and neuronal functions
06
Interacting drugs
PIN1 inhibitors (research and experimental): juglone, and synthetic small molecules targeting the PPIase domain
07
Biomarkers
PIN1 expression levels (often elevated in breast, prostate, lung, ovarian, gastric, esophageal, colorectal, cervical, melanoma, and brain tumors)PIN1 nuclear localizationGenetic polymorphisms in the *PIN1* promoter
Beyond the preview
Go deeper on Peptidyl-prolyl isomerase NIMA-interacting 1 (PIN1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptidyl-prolyl isomerase NIMA-interacting 1 (PIN1).